

Program of Coronary Angioplasty in Acute Myocardial Infarction in the Region of Murcia (Spain): APRIMUR Registry

Pilar Carrillo, Ramón López-Palop, Eduardo Pinar, Íñigo Lozano, Rocío Cortés, Daniel Saura, Josefa González, Francisco Picó and Mariano Valdés

Servicio de Cardiología. Hospital Universitario Virgen de la Arrixaca. Murcia.

Introduction and objectives. The geographic characteristic and healthcare facilities of the region of Murcia, Spain, are enough to assure that coronary angioplasty can be carried out in acute myocardial infarction according to current guidelines. The development of a regional program for coronary intervention in acute myocardial infarction may increase the number of patients who would benefit from reperfusion therapy in general and primary angioplasty in particular.

Material and methods. The program was initiated in April 2000 and had four steps: 1) Establishment of primary angioplasty as the treatment of choice of acute myocardial infarction in the regional reference hospital. 2) Application of phase 1 to a second hospital located 10 kilometers away from the reference hospital. 3) Extension of phase 1 to the entire city of Murcia. 4) Provision of facilities for coronary angioplasty in acute myocardial infarction to all patients in the region.

Results. Between January 2000 and August 2001, 392 angioplasties were performed for acute myocardial infarction. Primary angioplasty was performed in 92% and 85% of the patients with an indication for reperfusion therapy in phase 1 and 2, respectively. The median delay (indication to beginning of procedure) was 25 and 35 minutes in phases 1 and 2, respectively. Total mortality was 11,5% (5,2% in patients without shock at admission).

Conclusions. The design of a regional program of primary angioplasty may increase the number of patients who receive reperfusion therapy in compliance with current recommendations for the treatment of acute myocardial infarction.

Key words: Myocardial infarction. Coronary angioplasty. Registries.

Full English text available at: www.revespcardiol.org

SEE ARTICLE ON PAGES 565-7

Partially financed by the Fundación de Investigación Cardiológica Murciana.

Correspondence: Dr. Mariano Valdés Chávarri.
Servicio de Cardiología. Hemodinámica. Hospital Virgen de la Arrixaca.
Carretera Murcia-Cartagena, El Palmar 30120, Murcia, Spain.
E-mail: cateter@inicia.es

Received 11 October 2001
Accepted for publication 19 February 2001

Proyecto de un plan de accesibilidad al intervencionismo coronario en el infarto agudo de miocardio en la Región de Murcia (España). Registro APRIMUR

Introducción y objetivos. La Región de Murcia posee las características geográficas y la infraestructura suficiente para asegurar el empleo de la angioplastia coronaria en el infarto agudo de miocardio en los casos indicados según las vigentes guías de actuación. La elaboración de un plan regional de intervencionismo coronario en el infarto agudo de miocardio podría aumentar el número de pacientes beneficiados del tratamiento de reperusión en general, y de la angioplastia primaria en particular.

Material y métodos. El plan iniciado en abril de 2000 consta de 4 fases: 1) establecimiento de la angioplastia primaria como tratamiento de elección en el infarto en el hospital de referencia regional; 2) extensión de la fase 1 a un segundo hospital distante 10 km del hospital de referencia; 3) extensión de la fase 1 a toda la capital, y 4) facilitación al resto de la región de la angioplastia coronaria en el infarto agudo de miocardio.

Resultados. Entre enero de 2000 y agosto de 2001 se han realizado 392 angioplastias en el seno del infarto agudo de miocardio. El 92 y el 85% de los pacientes con indicación de tratamiento de reperusión recibieron angioplastia primaria en los hospitales implicados en las fases 1 y 2, respectivamente, con una mediana de retraso (indicación-inicio de angioplastia primaria) de 25 y 35 min, respectivamente. La mortalidad total fue del 11,5% (5,2% en los pacientes sin shock al ingreso).

Conclusiones. La elaboración de un plan regional y la utilización de la angioplastia primaria pueden aumentar el número de pacientes que reciba tratamiento de reperusión, aproximándose a las actuales recomendaciones terapéuticas en el infarto agudo de miocardio.

Palabras clave: Infarto de miocardio. Angioplastia coronaria. Registros.

INTRODUCTION

The annual incidence of new cases of acute myocardial infarction (AMI) in Spain has been estimated at 58 000 new cases.¹ General agreement exists that re-

ABBREVIATIONS

AMI: acute myocardial infarction.
 LBBB: left bundle-branch block.
 AHA: American Heart Association.
 ACC: American College of Cardiology.
 SEC: Sociedad Española de Cardiología.
 ICU: intensive care unit.

perfusion treatment, by either primary thrombolysis or angioplasty, is the most effective way to improve the short and long-term survival of these patients. The benefits that derive from applying reperfusion treatments are greater when the procedures are performed early and diminish to the point of disappearance when intervention is delayed,² although primary angioplasty could extend the time since onset of the symptoms of AMI in which patients can benefit from reperfusion treatment. Primary angioplasty has recently shown better results than thrombolysis in terms of reducing short and long-term mortality and salvaging myocardium.³⁻⁸ The use of angioplasty also extends the benefits of the reperfusion to patients in which thrombolysis is contraindicated.

Paradoxically, in spite of the broad consensus regarding the indications for reperfusion treatment, national and international registries show that these procedures are used in less than 50% of the patients considered «ideal candidates» for this treatment.⁹⁻¹³ The figures are even lower for patients who are not considered «ideal candidates» for reperfusion treatment, although they meet the criteria for its application in current practice guidelines in AMI.¹⁴⁻¹⁸ The scant use of primary angioplasty as a reperfusion technique in Spain and other countries, despite being considered the best reperfusion treatment for AMI, is noteworthy.

Given the superiority of primary angioplasty as a reperfusion treatment in AMI and the large percentage of patients who do not receive reperfusion treatment in spite of eligibility, we decided to promote from our cardiology department a regional plan for AMI care based on facilitating access to the hemodynamics laboratory of potential beneficiaries of AMI interventions according to present practice guidelines.

Program objectives:

1. To extend reperfusion treatment to all patients eligible according to the AMI practice guidelines of the SEC¹⁸ and AHA/ACC.¹⁴⁻¹⁷
2. To offer primary angioplasty as the treatment of choice in AMI.
3. To favor access to rescue angioplasty for patients in the region for which thrombolysis has not produced the desired result.

4. To establish a registry of interventionist activities in AMI and record the short and long-term results in the region of Murcia. This registry was named APRI-MUR (Angioplastia PRImaria en la región de MURcia [Primary Angioplasty in the region of Murcia]).

We report here the design of the regional program and the preliminary results of its first year of operation.

MATERIAL AND METHODS

Population and area of application

The Region of Murcia is a single-province autonomous community with 1 115 068 inhabitants according to the Provincial Delegation of Statistics. Half of the population reside in Murcia, Cartagena, and Lorca, the three largest municipalities, which have 349 040, 175 628, and 69 930 inhabitants, respectively. The region has nine hospitals pertaining to the public health-care system: three in the city of Murcia and six in different districts of the region. The capital, where the regional reference hospital is located, is situated in the geographic center of the region and connected by rail with seven of the eight remaining hospitals.




Fig. 1. Distribution of the hospitals of the public health service in the Region of Murcia and their distance by highway from the regional reference hospital.

Transfer times by highway are less than 1 h in every case (Figure 1). Five of the eight hospitals in the community have coronary units, all of them integrated in the intensive care services. There is no coronary unit integrated in a cardiology department in the region (Table 1).

About 600 patients with acute transmural infarctions are hospitalized in the region every year, according to figures from hospital coronary units in the autonomic community.

Infrastructure. Logistics

The regional reference hospital for hemodynamics and cardiac surgery is the Virgen de la Arrixaca University Hospital, located 7 km from the center of the city of Murcia. It has the only two hemodynamics laboratories that operate in the public healthcare system of Murcia. It is the only hospital with a cardiologist on call 24 h a day at the hospital and a hemodynamics teams that is continuously available. Its hemodynamics laboratory currently performs more than 1300 angioplasties a year and is staffed by 6 hemodynamics specialists who have complied with the requirements of the SEC and AHA/ACC for performing out scheduled and primary angioplasties in AMI.

Except during the workday, when telephone contact with the hemodynamics laboratory is direct, the hospital requesting the AMI intervention contacts the cardiologist on call of the regional reference hospital, who then alerts the hemodynamics team to come to the hospital. Patients are transferred by mobile ICU unit, generally belonging to the 061 emergency service. After the intervention the patient is transferred to the ICU of the reference hospital, unless the hemodynamic or clinical situation (electrical instability, the criterion of the hemodynamics specialist who performs the procedure, etc.) makes it inadvisable.

Design of the AMI angioplasty program

Given the scant tradition of primary angioplasty in the Region of Murcia, the program was designed with phases in which the availability of effective percutaneous AMI interventions would be expanded progressively.

Phase 1

Establishment of primary angioplasty as the treatment of choice for AMI in patients hospitalized in the hospital where the hemodynamics laboratory is located (Virgen de la Arrixaca University Hospital). Date of onset: April 2000.

Phase 2

Establishment of primary angioplasty as the treatment of choice for AMI in patients admitted to the second largest hospital in the city of Murcia (Hospital Morales Meseguer), located 10 km from the reference center. Date of onset: June 2000.

Phase 3

Establishment of primary angioplasty as the treatment of choice for AMI in patients in the city of Murcia. Incorporation of the third hospital of the city of Murcia (Hospital General Universitario).

Phase 4

To facilitate effective access to the rest of hospitals in the region to angioplasty for AMI (primary angioplasty, if indicated, and rescue angioplasty). Except in cases in which thrombolysis and rescue angioplasty are contraindicated, the use of primary angioplasty in each hospital is conditioned by the availability of the means to transfer patients in suitable circumstances within a reasonable time for the procedure to be effective (less than a hour between calling in the hemodynamics team and the patient's arrival at the reference

TABLE 1. Characteristics of the hospitals of the public health network of the Region of Murcia

	No. of beds	Coronary Unit	Cardiology specialty	Cardiologist on call
Virgen de la Arrixaca University Hospital (Murcia)	940	Yes	Yesa	Yes
Hospital Morales Meseguer (Murcia)	434	Yes	Yesb	No
Hospital General Universitario (Murcia)	80*	Yes	Yesb	No
Hospital Santa María del Rosell (Cartagena)	370	Yes	Yesb	No
Hospital de Los Arcos (San Javier)	95	No	Yesc	No
Hospital Rafael Méndez (Lorca)	224	Yes	Yesc	No
Hospital Comarcal del Noroeste (Caravaca)	105	No	Yesc	No
Hospital Virgen del Castillo (Yecla)	98	No	No	No
Hospital Fundación de Cieza (Cieza)	110	No	No	No

^aIndependent from the Department of Internal Medicine. ^bIntegrated as an independent section within the Department of Internal Medicine. ^cAs an undifferentiated part of the Department of Internal Medicine. *Provisional data (hospital under construction).

hospital). Date of onset: for primary angioplasty in patients without an absolute contraindication, this date will be determined by the achievement of adequate transfer conditions.

For the development of different phases, agreements were made with the intensive care units of different hospitals, as well as with the management of the 061 Service, to ensure patient transfer between hospitals in program phases 1, 2 and 3.

Design of the APRIMUR Registry

The main objective of this prospective, observational registry is to serve as a quality control of the AMI interventions performed in the Region of Murcia.

The registry, which is centralized in the regional hemodynamics laboratory, began 1 January 2000 and collects baseline clinical information, procedure data, hospital outcome, and events in the first year of all patients referred to the hemodynamics laboratory for AMI.

The main use of the registry is to analyze hospital and one-year mortality of the patients who undergo these procedures.

Registry inclusion criteria

The patients referred to our laboratory for primary angioplasty or rescue angioplasty were included in the registry.

Patients who meet the following two criteria and have not undergone thrombolysis for the treatment of AMI are considered candidates for primary angioplasty.¹⁴⁻¹⁷

- Symptoms compatible with myocardial ischemia lasting more than 30 min or persisting in spite of nitrite administration.

- ST-segment elevation of more than 1 mm in two or more contiguous electrocardiographic leads that persists for 30 min or more or after the administration of nitrites, or an undiagnostic electrocardiogram (ECG) showing complete left bundle-branch block (LBBB) or pacemaker rhythm.

The window of indication for primary angioplasty is the 12 h period beginning from the onset of symptoms, unless the symptoms or signs of myocardial ischemia persist.

The candidates for rescue angioplasty are patients who meet the above criteria and have received thrombolysis without having observed indirect signs of reperfusion 90 min after the administration of the thrombolysis. Angioplasties in which thrombolysis has been performed in the 12 h preceding the intervention are not considered primary.

All patients will be included in the registry according to the principle of *intention to treat*. All pa-

tients for which the hemodynamics laboratory is called in to perform a primary or rescue angioplasty will be included, whether or not the procedure is performed.

Data collection. Definition of variables

The data are collected prospectively. The medical history of the patient and characteristics of the AMI are obtained on arrival to the hemodynamics laboratory. The data related with the procedure are collected upon completion of the procedure by the physicians who intervene. The hospital outcome is obtained from the medical records of the patient after discharge to home. The one-month follow-up is conducted by an interview in the outpatient office. The follow-ups at 6 months and one year of the patients who do not return to the office for the one-month appointment are made by telephone. The collection of data and follow-up of patients who meet the inclusion criteria but do not undergo primary angioplasty are carried out prospectively in a similar way by means of the medical record, obtaining the same data, with the logical exception of those related with the intervention. The registry of the Hospital Virgen de la Arrixaca will be used to analyze retrospectively each year the medical records of the patients hospitalized with a diagnosis of AMI to determine whether or not they met criteria for inclusion in the program.

Two grant holders, one physician, and one nurse are in charge of collecting data from the registry under the supervision of a member of the regional hemodynamics laboratory.

The procedure was considered successful when a TIMI III flow was obtained in the artery responsible for AMI at the end of the procedure without major complications in the hemodynamics laboratory (death or cerebrovascular accident). The presence of cardiogenic shock at the time of admission was considered if the patient presented an invasive blood pressure <90 mm Hg with signs of peripheral hypoperfusion (cold sweating, pallor of skin and mucous membranes, obtundation, etc.) in the absence of triggering drugs.

Statistical analysis

The APRIMUR Registry has the statistical design of a prospective observational study. Qualitative variables are expressed as percentages and quantitative variables are expressed as the mean and standard deviation. The time variables are expressed as medians (25th-75th percentile) because they did not meet normality criteria.




Fig. 2. Distribution by hospital of the origin of patients referred for AMI interventions.

PRELIMINARY RESULTS

From 1 January 2000 to 31 August 2001, 392 patients were referred to our laboratory for primary angioplasty or rescue angioplasty (231 from 1 January to 31 August 2001). From the overall group of patients, 355 (90.6%) were referred for primary angioplasty.

From the beginning of phase 1 of the program (1-4-2000), primary angioplasty was indicated for 201 patients who were hospitalized in the hospital where the hemodynamics laboratory is located, which represents 92% of the patients who were hospitalized in this center with AMI and an indication for reperfusion treatment. The reasons why primary angioplasty was not performed in the remaining 16 patients were: *a*) occupation of the hemodynamics team with another AMI, 2 patients (1%); *b*) refusal of the patient to undergo catheterization, 1 patient (0.5%); *c*) very poor baseline situation of the patient before AMI, 8 patients (4%); *d*) unfavorable coronary anatomy, 2 patients (1%), and *e*) criterion of responsible physician, 3 patients (1.5%). Six of these 16 patients (3%) underwent thrombolysis.

From the beginning of phase 2 (1-6-2000), primary angioplasty has been indicated in 84 patients, who represent 85% of the patients hospitalized in the

Hospital Morales Meseguer of the city of Murcia with meet AMI criteria and have an indication for reperfusion treatment. The causes for not indicating primary angioplasty in the 10 remaining patients were: *a*) unavailability of a mobile ICU for transfer in 2 cases (2%); *b*) occupation of the hemodynamics team with another case of AMI in 2 cases (2%), and *c*) criterion of the responsible physician in the 6 remaining cases (6%).

Phases 3 and 4 are in their initial stage, so that, currently, the indication for primary angioplasty in the other centers in the region depends on the criterion of the attending physician guided by the characteristics of presentation of the AMI, presence of contraindications for thrombolysis, and availability of a mobile ICU to transfer the patients in a reasonable time. In Figure 2 is shown the origin of the patients for primary and rescue angioplasty. On six occasions, the 061 emergency service directly contacted the hemodynamics laboratory and transferred the patient without previous admission to the reference hospital. The delay in carrying out the examination from the onset of symptoms and from the moment the indication is established is shown in Table 2. Patients from all the hospitals outside the capital had a median delay of more than one hour from the moment the indication for primary angioplasty was established to its performance,

TABLE 2. Delay from the onset of symptoms to the beginning of the procedure and from the call to the hemodynamics team to the beginning of the procedure according to hospital where the indication was made (only primary angioplasties, n=355)

	Times		
	No. of primary angioplasties	Onset of symptoms-beginning of procedure	Call to hemodynamics team-beginning of procedure
061 Emergency Service	6	90 (80-160)	45 (45-45)
Virgen de la Arrixaca University Hospital (Murcia)	201	160 (100-245)	25 (15-30)
Hospital Morales Meseguer (Murcia)	84	180 (129-255)	35 (28-50)
Hospital General Universitario (Murcia)	17	152 (110-177)	37 (28-55)
Hospital Santa María del Rosell (Cartagena)	31	210 (170-350)	90 (82-125)
Hospital The Arcs (San Javier)	6	237 (110-305)	88 (75-115)
Hospital Rafael Méndez (Lorca)	4	370 (365-545)	120 (115-165)
Hospital Comarcal del Noroeste (Caravaca)	1	495	315
Hospital Virgen del Castillo (Yecla)	0	—	—
Hospital Fundación de Cieza (Cieza)	5	300 (150-390)	60 (55-65)

All values referring to times are expressed as medians (25th-75th percentile) in minutes.

and in most cases more than 90 min. On the contrary, the times for the hospitals in the city of Murcia were similar to those recorded in the reference hospital.

The growth of monthly activity in relation to the previous year (1999) is shown in Figure 3.

The baseline characteristics of the patients who underwent primary angioplasty are shown in Table 3. The mean age of the patients was 64 ± 12 years, and 75% of the patients were men. Of the 154 patients referred from other centers, 124 returned to the intensive care unit of the referring hospital. The 30 remaining patients were hospitalized in the intensive care unit of our center because it was thought that the

transfer could be harmful for the patient's clinical situation.

In 23 patients, the lesion responsible for the infarction was not found (6.5%). In 44% (8 patients) of the cases of suspected AMI of indeterminate location with suggestive symptoms and LBBB in the ECG (18 patients), coronary lesions were not observed.

The data related with the procedure performed and the hospital evolution in terms of mortality are shown in Table 4. Angiographic success was achieved in 82% of the patients. The hospital mortality was 11.5% of the entire group of patients analyzed by intention to treat, 10.7% in those who reached the hemodynamics




Fig. 3. Evolution of AMI interventions in the Region of Murcia since 1999.

laboratory alive, and 5.2% in those that did not present cardiogenic shock at time of admission.

DISCUSSION

Need for a regional AMI intervention program. Justification of objectives

Extension of reperfusion treatment to all patients who have an indication

The first goal of the program is to comply with currently effective AMI practice guidelines in most of the patients.^{14,15-17} Establishment of primary angioplasty as the treatment of choice in the hospitals involved in phases 1 and 2 of the program has made it possible to use reperfusion treatment in more than 95%, a figure much higher than has been reported in other registries published to date.

In Spain, it is not known what percentage of patients with AMI and an indication for reperfusion treatment receive such treatment when they come in contact with the healthcare system. Data from different national registries, none referring to the entire national population, report figures for reperfusion treatment of 34% to 43%,^{9,13} although in most cases it is not possible to ascertain what percentage of the patients who were included had an indication for this treatment. In the GESIR study¹¹ of 521 patients under the age of 75 years hospitalized with transmural AMI, after excluding patients with a non-definitive electrocardiographic diagnosis and those seen in the emergency room after the accepted time for reperfusion, only 62% of the patients received thrombolytic treatment. Outside of Spain, in the U.S., the NRMII2 data (National Registry of Myocardial Infarction 2) indicate that among the patients who are «ideal candidates» for reperfusion treatment (with less than 6 h of evolution of the AMI), only 39.8% receive it.¹⁹ Therefore, in spite of the theoretical availability of thrombolytic treatment and its easy applicability, less than half of the eligible patients receive it in clinical practice.

In contrast with the idea that primary angioplasty is theoretically less applicable, our data from the two centers participating in phases 1 and 2 of the regional program demonstrate that in certain conditions the use of primary angioplasty as the treatment of choice in AMI can bring routine clinical practice closer to the theoretical goal of making reperfusion treatment available to more of the patients who can benefit from it.

Extension of primary angioplasty as the treatment of choice in AMI

In spite of the fact that many studies have demonstrated the benefits of primary angioplasty compared to thrombolysis in the treatment of AMI,^{4,5-8} this procedu-

TABLE 3. Baseline characteristics of patients referred for primary angioplasty (n=355)

Mean age	64±12
Percentage of patients >74 years	81 (23%)
Percentage of patients >80 years	39 (11%)
Female sex	87 (25%)
Hypertension	172 (48%)
Smoking	162 (46%)
Hypercholesterolemia	23 (83%)
Diabetes	97 (27%)
Previous CVA	22 (6,2%)
Previous MI	83 (23%)
Previous CRS	9 (2,5%)
Previous PTCA	33 (9,3%)
Anterior location	156 (44%)
LBBB	18 (5%)
Shock at admission:	45 (12,7%)
Delay from onset of symptoms-beginning PTCA*	170 (115-270)
Deceased before PTCA	4 (1,1%)
Referrals from other hospitals:	154 (43,4%)
Transfers to other hospitals after PTCA	124 (35%)

CVA indicates cerebrovascular accident; MI, myocardial infarction; CRS, coronary revascularization surgery. *Expressed as median(25th-75th percentiles).

TABLE 4. Data related with the procedure and hospital evolution of the patients referred for primary angioplasty (n=355)

Coronary intervention	322 (91%)
Successful procedure	297 (92%)
Stent implantation	300 (93%)
IIB/IIIa platelet antagonists	212 (60%)
Intra-aortic balloon counterpulsation	23 (7%)
No. of vessels treated per procedure	1.8±0.4
No. of lesions treated per procedure	1,31±0,7
Coronary artery treated	
Common trunk	6 (2%)
Anterior descending	134 (38%)
Circumflex	42 (12%)
Right coronary	126 (35%)
Saphenous graft	3 (0,8%)
Total hospital mortality*	41 (11,5%)
Mortality in patients without shock at admission*	16 (5,2%)

*Includes patients in which catheterization was indicated who died before it was performed.

re has not become generalized in clinical practice. According to the data of the activity registry of the Section of Hemodynamics and Interventionist Cardiology of 1999, 1791 primary angioplasties were performed in Spain that year.²⁰ The number rose in the year 2000 to 2149 (data from the web page of the Sección de Hemodinámica: <http://www.hemodinamica.com/registros/200/diapo19.jpg>).

It is not possible to accurately determine what percentage these figures represent with respect to the total number of myocardial infarctions with an indication for reperfusion that occur annually in Spain. The num-

ber of patients discharged alive or who died in 1990 with the diagnosis of AMI was 27 642,²¹ although it is considered that more than 50 000 new myocardial infarctions take place every year.¹ In the RISCO registry (whose participating centers represent only 5385 of all the infarctions that occurred in Spain in 1999), thrombolysis was performed in 2364 patients, a figure that exceeds the number of primary angioplasties made in year 2000. In the U.S. 7% of the patients underwent primary angioplasty versus 21% of those that underwent thrombolysis in 1999.²² In the Region of Murcia only 18 interventionist procedures were performed for AMI in 1999 (Figure 3). The lack of sufficient infrastructure to effectively carry out AMI interventions is the most likely explanation of this discrepancy between the recommendations of scientific evidence and routine clinical practice. In our experience, keeping a team on call 24 h a day, 7 days a week, with no time constraints for performing primary angioplasty, and the expansion of the service as a result of concentrating all interventionist activity in the region in a single center, made it possible to perform primary angioplasty on almost all the patients with AMI who had an indication for reperfusion treatment in the hospitals integrated in phases 1 and 2.

Facilitating access to rescue angioplasty of patients in the region who undergo thrombolysis without obtaining the expected result

From 15% to 50% of the patients, depending on the series and thrombolytic used, do not present indirect signs of reperfusion after intravenous administration of the thrombolytic drug.²³⁻²⁵ In certain subgroups of these patients, a rescue angioplasty can re-establish bloodflow and improve the prognosis if performed promptly.²⁵ By improving patient transfer mechanisms and planning practice guidelines, it is possible to intervene effectively in such patients, who usually experience long delays because the time spent waiting for the thrombolytic to act is compounded by the time required to decide on a second form of reperfusion treatment. The time required to transfer patients from hospitals distant to the reference hospital (Table 2) is far from optimal. One of the aims of this program is to improve action in these patients, although the scant number of patients from distant hospitals, who may be patients highly selected with regard to the characteristics of AMI presentation and a worse hemodynamic situation, at present precludes drawing conclusions.

Establish a registry of interventionist activity in AMI and its short and long-term results in the Region of Murcia

The main objective of creating and maintaining a prospective registry of interventionist activity in AMI

is quality control, especially when treatment is carried out in patients of which more than 50% are referred from other hospitals. The APRIMUR Registry complements the registry of our service for coronary interventionist activity in general. The second objective of the registry is to know the results of primary angioplasty in a clinical context, especially in centers where it has been established as the treatment of choice for AMI. The knowledge that clinical trials generally exclude patients at highest risk^{26,27} is, in our opinion, very important to understanding the results of the practical application of primary angioplasty to existing practice guidelines.

Preliminary results

As has been commented, the results of the first year of our program demonstrate that the application of primary angioplasty can yield better reperfusion results than the mean obtained with thrombolysis in most registries published to date.^{9-13,19} The median delay observed in the three hospitals of the capital (Table 2) is less than 40 min from the moment that the reperfusion indication is established to the beginning of angioplasty. This delay is clearly shorter than the time lapse from randomization to angioplasty reported in previous clinical trials,^{3,28,29} although it is longer in patients coming from other hospitals in the region.

The mortality observed in the series is clearly superior to that observed in previous clinical trials of primary angioplasty.⁴⁻⁶ This difference can probably be explained, as commented, by the selection of the most favorable patients in randomized studies, accentuated by the selection of patients at greater risk in hospitals distant from the reference center. Accordingly, the treated population has a higher percentage of shock at the time of admission and an older mean age than those included in previous clinical trials. As a result of the continuation of the regional program in upcoming months, we should obtain more trustworthy data on the results of this procedure and its applicability in centers distant from the hospital where the hemodynamics laboratory is located.

LIMITATIONS

The full operation of this program, especially the last two phases, will require the collaboration of health authorities and the coordination of all the groups involved to obtain an effective diagnosis and treatment of patients. As the distance from the reference hospital increases, so do the possibilities of failure in the chain from the onset of AMI to the restoration of blood flow in the artery responsible for infarction. In order to obtain the desired results, problems inherent to the transfer of patients and the logical increase in the work load of the reference center will have to be solved.

The APRIMUR Registry is exhaustive with respect to interventionist activity in AMI in the public health-care system of the Region of Murcia. In order to collect all the activity of the region, the activity carried out at two private laboratories would have to be included. However, the small number of AMI procedures performed at these centers (less than 3 in the year 2000) indicates that their exclusion from the overall analysis of results in the region is not very influential.

Since the main objective of this article is to present this regional project, which is in its initial phases, the available results have been analyzed in detail. As the development of the program advances, these analyses will reflect still better the results obtained.

CONCLUSIONS

The program for improving accessibility to coronary interventions for AMI in the Region of Murcia tries to bring the therapeutic procedures that have been demonstrated to produce that greatest benefits in the treatment of the AMI into routine use: reperfusion treatment, particularly primary angioplasty. The use of primary angioplasty as the treatment of choice for AMI can increase the percentage of patients who receive reperfusion treatment, thus coming closer to following the recommendations made in practice guidelines. The parallel development of a registry of the interventions for AMI performed and their results (APRIMUR Registry) provides the necessary quality control for the program and makes it possible to evaluate the consequences of generalizing the use of primary angioplasty as reperfusion treatment for AMI.

REFERENCES

1. Navarro-López F, Pare JC. Infarto agudo de miocardio. En: Diagnóstico clínico en cardiología. Barcelona: Editorial Médica JIMS, 1997; p. 118.
2. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1,000 patients. *Lancet* 1994;343:311-22.
3. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. *N Engl J Med* 1993;328:673-9.
4. Zijlstra F, DeBoer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. *N Engl J Med* 1993;328:680-4.
5. Weaver WD, Simes RJ, Betriu A, Grines CL, Zijlstra F, García E, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. *JAMA* 1997;278:2093-8.
6. García E, Elízaga J, Pérez-Castellano N, Serrano JA, Soriano J, Abeytua M, et al. Primary angioplasty versus systemic thrombolysis in anterior myocardial infarction. *J Am Coll Cardiol* 1999;33:605-11.
7. Zijlstra F, Hoorntje JC, de Boer MJ, Reiffers S, Miedema K, Ottervanger JP, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. *N Engl J Med* 1999;341:1413-9.
8. Velianou JL, Wilson SH, Reeder GS, Caplice NM, Grill DE, Holmes DRJ, et al. Decreasing mortality with primary percutaneous coronary intervention in patients with acute myocardial infarction: the Mayo Clinic experience from 1991 through 1997. *Mayo Clin Proc* 2000;75:994-1001.
9. Cabadés A, Valls F, Echanove I, Francés M, Sanjuan R, Calabuig J, et al. Estudio RICVAL. El infarto agudo de miocardio en la ciudad de Valencia. Datos de 1.124 pacientes en los primeros 12 meses del Registro (diciembre de 1993-noviembre de 1994). Investigadores del RICVAL. *Rev Esp Cardiol* 1997;50:383-96.
10. Cabadés A, López-Bescós L, Arós F, Loma-Osorio A, Bosch X, Pabón P, et al. Variabilidad en el manejo y pronóstico a corto y medio plazo del infarto de miocardio en España: el estudio PRIAMHO. Proyecto de Registro de Infarto Agudo de Miocardio Hospitalario. *Rev Esp Cardiol* 1999;52:767-75.
11. Péraire M, Martín-Baranera M, Pallarés C, componentes del grupo GESIR-5. Impacto de la trombólisis sobre la supervivencia a corto y largo plazo de una cohorte de pacientes con infarto agudo de miocardio atendidos de forma consecutiva en todos los hospitales de una región sanitaria. Estudio GESIR-5. *Rev Esp Cardiol* 2001;54:150-8.
12. Fiol M, Cabadés A, Sala J, Marrugat J, Elosua R, Vega G, et al. Variabilidad en el manejo hospitalario del infarto agudo de miocardio en España. Estudio IBERICA (Investigación, Búsqueda Específica y Registro de Isquemia Coronaria Aguda). *Rev Esp Cardiol* 2001;54:443-52.
13. Arós F, Loma-Osorio A, Bosch X, González J, López-Bescós L, Marrugat J, et al. Manejo del infarto de miocardio en España (1995-99). Datos del registro de infartos de la Sección de Cardiopatía Isquémica y Unidades Coronarias (RISCI) de la Sociedad Española de Cardiología. *Rev Esp Cardiol* 2001;54:1033-40.
14. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). *Circulation* 1996;94:2341-50.
15. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). *J Am Coll Cardiol* 1996;28:1328-428.
16. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, et al. 1999 update; ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). *Circulation* 1999;100:1016-30.
17. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). *J Am Coll Cardiol* 1999;34:890-911.
18. Arós F, Loma-Osorio A, Alonso A, Alonso J, Cabadés A, Coma-Canella I, et al. Guías de actuación clínica de la Sociedad Española de Cardiología en el infarto agudo de miocardio. *Rev Esp Cardiol* 1999;52:919-56.
19. Barron HV, Bowly LJ, Breen T, Rogers WJ, Canto JG, Zhang

- Y, et al. Use of reperfusion therapy for acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2. *Circulation* 1998;97:1150-6.
20. Soriano J, Alfonso F, Cequier A, Moris C. Registro de actividad de la Sección de Hemodinámica y Cardiología Intervencionista del año 1999. *Rev Esp Cardiol* 2000;53:1626-38.
 21. Martínez M, Slacer A. Mortalidad en España en 1994. *Boletín Epidemiológico Semanal* 1997;5:57-68.
 22. Rogers WJ, Canto JG, Lambrew CT, Tiefenbrunn AJ, Kinkaid B, Shoultz DA, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. *J Am Coll Cardiol* 2000;36:2056-63.
 23. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. *N Engl J Med* 1993;329:1615-22.
 24. Krucoff MW, Croll MA, Pope JE, Pieper KS, Kanani PM, Granger CB, et al. Continuously updated 12-lead ST-segment recovery analysis for myocardial infarct artery patency assessment and its correlation with multiple simultaneous early angiographic observations. *Am J Cardiol* 1993;71:145-51.
 25. Ellis SG, da Silva E, Heyndrickx G, Talley JD, Cemigliano C, Steg G, et al. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction. *Circulation* 1994;90:2280-4.
 26. Jha P, Deboer D, Sykora K, Naylor CD. Characteristics and mortality outcomes of thrombolysis trial participants and nonparticipants: a population-based comparison. *J Am Coll Cardiol* 1996;27:1335-42.
 27. López-Sendón JL. Utilidad y limitaciones de los registros en el infarto agudo de miocardio. El estudio PRIAMHO. *Rev Esp Cardiol* 2000;53:477-8.
 28. Berger PB, Bell MR, Holmes DR Jr, Gersh BJ, Hopfenspirger M, Gibbons R. Time to reperfusion with direct coronary angioplasty and thrombolytic therapy in acute myocardial infarction. *Am J Cardiol* 1994;73:231-6.
 29. Berger PB, Ellis SG, Holmes DR Jr, Granger CB, Criger DA, Betriu A, et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. *Circulation* 1999;100:14-20.